Trial · NCT03037385
Results by group375
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 375
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Phase 1 : Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Pralsetinib | Phase 1: All Participants QD | MTD | 400 | mg | |
| Phase 1 : Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Pralsetinib | Phase 1: All Participants QD | RP2D | 400 | mg | |
| Phase 1 and Phase 2: Number of Participants With AEs and Serious AEs (SAEs) | Pralsetinib ≤ 300 mg QD | AEs | 37 | percentage of participants | |
| Phase 1 and Phase 2: Number of Participants With AEs and Serious AEs (SAEs) | Pralsetinib 400 mg QD | AEs | 540 | percentage of participants | |
| Phase 1 and Phase 2: Number of Participants With AEs and Serious AEs (SAEs) | Pralsetinib BID Dosing Schedule | AEs | 9 | percentage of participants | |
| Phase 1 and Phase 2: Number of Participants With AEs and Serious AEs (SAEs) | Pralsetinib All Doses | AEs | 590 | percentage of participants | |
| Phase 1 and Phase 2: Number of Participants With AEs and Serious AEs (SAEs) | Pralsetinib ≤ 300 mg QD | SAEs | 26 | percentage of participants | |
| Phase 1 and Phase 2: Number of Participants With AEs and Serious AEs (SAEs) | Pralsetinib 400 mg QD | SAEs | 381 | percentage of participants | |
| Phase 1 and Phase 2: Number of Participants With AEs and Serious AEs (SAEs) | Pralsetinib BID Dosing Schedule | SAEs | 7 | percentage of participants | |
| Phase 1 and Phase 2: Number of Participants With AEs and Serious AEs (SAEs) | Pralsetinib All Doses | SAEs | 416 | percentage of participants | |
| Phase 2: Overall Response Rate (ORR) | RET- Fusion Positive NSCLC With Prior Platinum Treatment: | 63.1 | 95% Confidence Interval 54.2 to 71.4 | percentage of participants | |
| Phase 2: Overall Response Rate (ORR) | RET-fusion Positive NSCLC With Non-platinum Systemic Treatment | 73.9 | 95% Confidence Interval 51.6 to 89.8 | percentage of participants | |
| Phase 2: Overall Response Rate (ORR) | RET-fusion Positive NSCLC With No Prior Systemic or Platinum Treatment | 78.3 | 95% Confidence Interval 69.2 to 85.7 | percentage of participants | |
| Phase 2: Overall Response Rate (ORR) | RET-mutation MTC With Prior Cabozantinib and/or Vandetanib Treatment | 56.7 | 95% Confidence Interval 43.2 to 69.4 | percentage of participants | |
| Phase 2: Overall Response Rate (ORR) | RET-mutation MTC With No Prior Cabozantinib or Vandetanib Treatment | 77.8 | 95% Confidence Interval 66.4 to 86.7 | percentage of participants | |
| Phase 2: Overall Response Rate (ORR) | RET-fusion Positive TC | 85.2 | 95% Confidence Interval 66.3 to 95.8 | percentage of participants | |
| Phase 2: Overall Response Rate (ORR) | RET-fusion Positive Solid Tumors Other Than NSCLC and TC | 46.4 | 95% Confidence Interval 27.5 to 66.1 | percentage of participants | |
| Phase 2: Overall Response Rate (ORR) | RET-altered Solid Tumors Previously Treated With RET Inhibitor | 19.0 | 95% Confidence Interval 5.4 to 41.9 | percentage of participants | |
| Phase 2: Overall Response Rate (ORR) | RET-mutation Positive Tumors Other Than MTC | 7.7 | 95% Confidence Interval 0.99 to 36.0 | percentage of participants | |
| Phase 1: ORR | Phase I: Pralsetinib 30 mg | 0 | 95% Confidence Interval NA to NA | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03037385/results